277 related articles for article (PubMed ID: 10197041)
1. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
Shi Q; Chen K; Morris-Natschke SL; Lee KH
Curr Pharm Des; 1998 Jun; 4(3):219-48. PubMed ID: 10197041
[TBL] [Abstract][Full Text] [Related]
2. Tubulins - the target for anticancer therapy.
Vindya NG; Sharma N; Yadav M; Ethiraj KR
Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
[TBL] [Abstract][Full Text] [Related]
4. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
Dong M; Liu F; Zhou H; Zhai S; Yan B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
[TBL] [Abstract][Full Text] [Related]
5. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
6. Antimicrotubular drugs binding to vinca domain of tubulin.
Gupta S; Bhattacharyya B
Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
[TBL] [Abstract][Full Text] [Related]
7. Natural products as antimitotic agents.
Dall'Acqua S
Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355
[TBL] [Abstract][Full Text] [Related]
8. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
9. Physiochemical aspects of tubulin-interacting antimitotic drugs.
Correia JJ; Lobert S
Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel anticancer bivalent colchicine-tubulizine hybrids.
Malysheva YB; Combes S; Allegro D; Peyrot V; Knochel P; Gavryushin AE; Fedorov AY
Bioorg Med Chem; 2012 Jul; 20(14):4271-8. PubMed ID: 22739088
[TBL] [Abstract][Full Text] [Related]
12. Computational design and biological testing of highly cytotoxic colchicine ring A modifications.
Torin Huzil J; Winter P; Johnson L; Weis AL; Bakos T; Banerjee A; Luduena RF; Damaraju S; Tuszynski JA
Chem Biol Drug Des; 2010 Jun; 75(6):541-50. PubMed ID: 20408852
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents.
Xia Y; Yang ZY; Xia P; Hackl T; Hamel E; Mauger A; Wu JH; Lee KH
J Med Chem; 2001 Nov; 44(23):3932-6. PubMed ID: 11689079
[TBL] [Abstract][Full Text] [Related]
14. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
15. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
16. Anticancer drug design based on plant-derived natural products.
Lee KH
J Biomed Sci; 1999; 6(4):236-50. PubMed ID: 10420081
[TBL] [Abstract][Full Text] [Related]
17. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Mooberry SL; Taoka CR; Busquets L
Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
[TBL] [Abstract][Full Text] [Related]
18. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
[TBL] [Abstract][Full Text] [Related]
20. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
Bhattacharyya B; Panda D; Gupta S; Banerjee M
Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
